Biomerica has gained approval from the UAE Ministry of Health and Prevention (MOHAP) for its Fortel prostate-specific antigen (PSA) screening test used in the early identification of prostate cancer.

Utilising a finger-prick blood sample, the test claims to generate ‘accurate’ outcomes within ten minutes by measuring elevated PSA levels, an early marker of the disease.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This rapid diagnostic tool aims to alleviate the strain on healthcare systems and enhance patient outcomes by enabling early identification.

Following the introduction of the EZ Detect colon disease at-home screening test in Dubai, which received government insurance reimbursement, Biomerica is currently focused on similar achievements with the Fortel test, having established partnerships with distributors and secured essential regulatory approvals in the region.

The company noted that the test has shown potential in clinical evaluations. A study demonstrated a sensitivity, specificity, and accuracy of 100%, 95%, and 97.5% respectively.

Further research conducted at Ain Shams University’s Faculty of Medicine in Egypt validated the effectiveness of the test, which achieved a sensitivity of 97.2%, a specificity of 96.2%, and an accuracy of 96.7%.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company continues to focus on delivering accessible, accurate, affordable, accurate diagnostic tools for early disease detection and treatment.

In May 2023, the company announced the validation of its inFoods IBS test for use with finger stick (capillary) patient whole blood samples for irritable bowel syndrome.

Biomerica’s portfolio continues to grow as the company develops and markets diagnostic and therapeutic products for point-of-care and clinical laboratory applications.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact